

## CONSIDERATIONS OF ALTERNATIVE METHODS ON TESTING PROPOSALS IN YOUR REGISTRATION

Please complete this form and provide information for each of the points below.

If you have more than one testing proposal, please copy and paste the three bullet points within the same document and complete the details as appropriate for each testing proposal.

This document will be published on ECHA website along with the third party consultation on the testing proposal(s).

Public substance name: N-{2-[(phenylcarbamoyl)amino]phenyl}benzenesulfonamide EC Number (omit if confidential): 806-543-7 CAS Number (omit if confidential): 215917-77-4

Date of considerations: 12 November 2015

• Hazard endpoint for which vertebrate testing was proposed:

Genetic toxicity in vivo with the registered substance;

- Considerations that the general adaptation possibilities of Annex XI of the REACH Regulation were not adequate to generate the necessary information (instruction: please address all points below):
  - available GLP studies None
  - available non-GLP studies None
  - historical human data None and not relevant
  - (Q)SAR Not adequate according to ECHA guidance document\*
  - *in vitro* methods Already available, but further in vivo data needed
  - weight of evidence
    Not adequate and no relevant data available according to ECHA guidance document\*
  - grouping and read-across Not relevant and not possible
  - substance-tailored exposure driven testing [if applicable] Not applicable
  - [approaches in addition to above [if applicable] Not applicable
  - other reasons [if applicable] Not applicable
- Considerations that the specific adaptation possibilities of Annexes VI to X (and column 2 thereof) were not applicable (instruction: free text):

Test proposal is fully in line with ECHA guidance document\*, and can neither be replaced by in vitro testing nor by using other data from other substances.

\* Chapter R.7a: Endpoint specific guidance Version 4.1 – October 2015